Therapeutic Area News

Nov, 2006

News / Therapeutic Area News

Nov 15, 2006

OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 15, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Committee...

Oct, 2006

News / Therapeutic Area News

Oct 29, 2006

Astellas Pharma US, Inc., GlaxoSmithKline, and VESIcare® (solifenacin succinate) Sponsor the #18 Race Car at Atlanta Motor Speedway to Raise Awareness about Overactive Bladder

Atlanta, GA (October 29, 2006) — It is estimated that 17 million men and women in the United States, especially those age 50 and older, may have a common yet under-recognized medical condition,...

Sep, 2006

News / Therapeutic Area News

Sep 21, 2006

OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has begun a Phase III clinical trial of Tarceva® (erlotinib) as a targeted...

Jul, 2006

News / Therapeutic Area News

Jul 27, 2006

OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--July 28, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Roche, its international partner for Tarceva® (erlotinib), received a negative...

News / Therapeutic Area News

Jul 25, 2006

Study Demonstrates Improved Renal Function and Lipid Values in Kidney Transplant Patients on Prograf® Compared to Patients Taking Neoral®

BOSTON, July 25, 2006 – Research presented today at the World Transplant Congress (WTC) revealed that after only six months post-conversion from Neoral® (cyclosporine or CsA) to Prograf®...